Dr. Reddy's Glimepiride Tablets Recalled Nationwide Over Tablet Misprint: Supply Chain Implications
Dr. Reddy's Laboratories, Inc. has initiated a Class III recall of 14,425 bottles of Glimepiride Tablets, USP 1mg, across the U.S. due to a tablet misprint. This voluntary action, stemming from its Indian manufacturing arm, highlights critical quality control vulnerabilities. Procurement and regulatory teams must assess supplier quality systems and potential supply disruptions for this essential diabetes medication.
FDA Initiates Class III Recall for Dr. Reddy's Glimepiride Tablets Due to Misprint
The U.S. Food and Drug Administration (FDA) has classified a nationwide recall by Dr. Reddy's Laboratories, Inc. for its Glimepiride Tablets, USP 1mg, as Class III. This voluntary, firm-initiated recall, identified by the reference number D-0313-2024, commenced on January 18, 2024, and remains ongoing. The primary reason for this regulatory action is a 'misprint on tablet,' affecting specific lots of the product. This Class III classification indicates that while the misprint is a deviation from quality standards, it is unlikely to cause adverse health consequences. However, for procurement directors and regulatory affairs heads, any deviation in product quality, especially for a widely prescribed medication like Glimepiride, necessitates immediate attention. The affected product, packaged in 500-count bottles with NDC 55111-320-05, includes lot numbers T2303609 and T2303610, both with an expiration date of June 2026. A total of 14,425 bottles are subject to this recall. For supply chain VPs, this event underscores the critical importance of stringent quality control at every stage of manufacturing and packaging, as even seemingly minor defects can trigger significant logistical and compliance burdens. The recall affects other NDCs as well, including 55111-320, 55111-321, and 55111-322, covering various package sizes and strengths within the Glimepiride product family, indicating a broader potential impact on inventory management and patient access to this sulfonylurea medication.
Manufacturing Origin and Product Profile: Glimepiride's Global Supply Chain
The recalled Glimepiride Tablets, USP 1mg, are manufactured by Dr. Reddy's Laboratories Limited in Srikakulam-532 409, INDIA, with distribution handled by Dr. Reddy's Laboratories, Inc. from its Princeton, NJ, United States, facility. This dual-entity structure highlights the globalized nature of pharmaceutical supply chains, where manufacturing often occurs in one geography while distribution and recall management are handled by a local subsidiary. Glimepiride, a sulfonylurea compound, is a critical human prescription drug used in the management of type 2 diabetes, making its consistent and compliant supply essential for patient care. The product's application number is ANDA077091, signifying its status as an approved generic drug. For business development executives, understanding the manufacturing footprint and regulatory compliance history of international partners is paramount when evaluating potential collaborations or market entry strategies. The reliance on overseas manufacturing sites introduces complexities related to varying regulatory oversight and quality assurance practices, demanding robust due diligence. The incident reinforces the need for procurement teams to not only vet the distributing entity but also to gain full transparency into the actual manufacturing sites and their adherence to cGMP standards, particularly for high-volume generic medications like Glimepiride.
Nationwide Supply Chain Exposure for Glimepiride Tablets
The distribution pattern for the recalled Glimepiride Tablets, USP 1mg, is described as 'Nationwide' across the United States. This broad reach means that pharmacies, wholesalers, and healthcare providers throughout the country are potentially impacted by this recall. With 14,425 bottles of the 500-count size affected, the logistical challenge for Dr. Reddy's Laboratories, Inc. and its downstream partners is substantial, despite the Class III classification. For supply chain VPs, this event underscores the necessity of having robust recall procedures in place, capable of rapidly identifying, isolating, and returning affected products from a vast distribution network. The potential for temporary stockouts or disruptions in the supply of Glimepiride, even if quickly resolved, can have ripple effects on patient management for type 2 diabetes. Regulatory affairs heads must ensure that all communication and recall execution adhere strictly to FDA guidelines, minimizing both compliance risk and market disruption. Furthermore, business development executives should recognize that such recalls, even for minor defects, can influence brand perception and market trust, impacting future sales and partnership opportunities within the competitive generic drug landscape.
Strategic Sourcing: Identifying Alternative Glimepiride Suppliers
Given the recall of Glimepiride Tablets, USP 1mg, by Dr. Reddy's Laboratories, Inc., procurement directors must critically evaluate their current sourcing strategies for this essential diabetes medication. While our current intelligence does not identify specific alternative suppliers for Glimepiride from the provided Knowledge Graph, the generic nature of the drug suggests the existence of multiple manufacturers. The absence of readily available alternative supplier data in this context highlights a potential vulnerability for organizations heavily reliant on a single source. For supply chain VPs, this incident serves as a clear directive to diversify their supplier base for critical generic drugs. Qualifying new suppliers for Glimepiride involves a rigorous process, including facility audits, quality system assessments, and bioequivalence studies, which can take several months to over a year. Therefore, proactive identification and pre-qualification of secondary or tertiary suppliers are crucial for maintaining supply chain resilience. Business development executives should monitor the market for other FDA-approved manufacturers of Glimepiride to understand the competitive landscape and identify potential partners who demonstrate consistent quality and regulatory compliance, thereby mitigating future supply risks and ensuring uninterrupted patient access to this vital medication.
Dr. Reddy's Regulatory Compliance and Remediation Outlook
While the provided Knowledge Graph does not detail Dr. Reddy's Laboratories' prior regulatory history, this Class III recall for Glimepiride Tablets, USP 1mg, signals a lapse in quality control that will undoubtedly draw FDA scrutiny. Even a voluntary, firm-initiated recall for a 'misprint on tablet' requires a comprehensive investigation into the root cause and the implementation of robust corrective and preventive actions (CAPA). For regulatory affairs heads, monitoring Dr. Reddy's response and remediation plan is crucial. The company will need to demonstrate to the FDA that its quality management system, particularly concerning labeling and visual inspection processes at the Srikakulam, India, manufacturing facility, has been thoroughly reviewed and improved to prevent recurrence. The 'Ongoing' status of the recall indicates that the process of retrieving affected product and implementing corrective measures is still in progress. Future FDA inspections may specifically target these areas, and any deficiencies could lead to more severe regulatory actions, such as Warning Letters or Import Alerts, which would have significant commercial implications. Procurement directors should engage with Dr. Reddy's to understand their CAPA plan and assess its effectiveness, ensuring that the supplier is committed to upholding the highest quality standards for all products sourced.